fatty diacid comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
One average square inch (6.5 cm2) of skin holds 650 sweat glands, 20 blood vessels, 60,000 melanocytes, and more than 1,000 nerve endings. The average human skin cell is about 30 μm in diameter, ranging from 25 to 40 μm2, depending on a variety of factors. Skin is composed of three primary layers: the epidermis, the dermis and the hypodermis (more commonly called the subcutaneous layer).
=== Media === In literature, characters believed to exhibit signs of BPD include Catherine in Wuthering Heights (1847), Smerdyakov in The Brothers Karamazov (1880), and Harry Haller in Steppenwolf (1927). Films have also attempted to portray BPD, with characters in Margot at the Wedding (2007), Mr. Nobody (2009), Cracks (2009), Truth (2013), Wounded (2013), Welcome to Me (2014), and Tamasha (2015) all suggested to show traits of the disorder. The behavior of Theresa Dunn in Looking for Mr. Goodbar (1975) is consistent with BPD, as suggested by Robert O. Friedel. Films like Play Misty for Me (1971) and Girl, Interrupted (1999, based on the memoir of the same name) suggest emotional instability characteristic of BPD, while Single White Female (1992) highlights aspects such as identity disturbance and fear of abandonment. Clementine in Eternal Sunshine of the Spotless Mind (2004) is noted to show classic BPD behavior, and Carey Mulligan's portrayal in Shame (2011) is praised by psychiatrists for its accuracy regarding BPD characteristics. Television series like Crazy Ex-Girlfriend (2015) and the miniseries Maniac (2018) depict characters with BPD. Traits of BPD and narcissistic personality disorders are observed in characters like Cersei and Jaime Lannister from A Song of Ice and Fire (1996) and its TV adaptation Game of Thrones (2011). In The Sopranos (1999), Livia Soprano is diagnosed with BPD, and even the portrayal of Bruce Wayne/Batman in the show Titans (2018) is said to include aspects of the disorder.
XLI Army Corps (mot.): 1st Panzer Division, 6th Panzer Division, 36th Motorised Infantry Division, 269th Infantry Division XXXXI Army Corps (mot.): 8th Panzer Division, 3rd Motorised Infantry Division, 290th Infantry Division 3rd SS Motorised Infantry Division Totenkopf 2nd SS Motorised Infantry Division Das Reich (during Operation Typhoon) The Army Group was to advance through the Baltic States to Leningrad. Barbarossa commenced on 22 June 1941 with a massive German attack along the whole front line. The 4th Panzer Group headed for the Dvina River to secure the bridges near the town of Daugavpils. The Red Army mounted a number of counterattacks against the XXXXI Panzer Corps, leading to the Battle of Raseiniai. After Reinhardt's corps closed in, the two corps were ordered to encircle the Soviet formations around Luga. Again having penetrated deep into the Soviet lines with unprotected flanks, Manstein's corps was the target of a Soviet counteroffensive from 15 July at Soltsy by the Soviet 11th Army. Manstein's forces were badly mauled and the Red Army halted the German advance at Luga. Ultimately, the army group defeated the defending Soviet Northwestern Front, inflicting over 90,000 casualties and destroying more than 1,000 tanks and 1,000 aircraft, then advanced northeast of the Stalin line. On 6 July 1941, Hoepner issued an order to his troops instructing them to treat the "loyal population" fairly, adding that "individual acts of sabotage should simply be charged to communists and Jews".
Sources: en.wikipedia.org
==== Slavery in the modern era ==== Brass, Tom; van der Linden, Marcel (1997). Free and unfree labour: the debate continues. Peter Lang. ISBN 978-3-906756-87-5. Brass, Tom (2015). Towards a Comparative Political Economy of Unfree Labour: Case Studies and Debates. Taylor & Francis. ISBN 978-1-317-82735-1. Bales, Kevin, ed. (2005). Understanding Global Slavery: A Reader. University of California Press. ISBN 978-0-520-93207-4. Bales, Kevin (2007). Ending Slavery: How We Free Today's Slaves. University of California Press. ISBN 978-0-520-25470-1. Craig, Gary (2007). Contemporary Slavery in the UK: Overview and Key Issues (PDF). York: Joseph Rowntree Foundation. ISBN 978-1-85935-573-2. Archived from the original (PDF) on June 14, 2007. Retrieved December 17, 2007. Hawk, David R. (2012). The Hidden Gulag: The Lives and Voices of "those Who Are Sent to the Mountains" (PDF). Washington, DC: U.S. Committee for Human Rights in North Korea. ISBN 978-0-615-62367-2. Archived from the original (PDF) on March 13, 2015. Retrieved September 21, 2012. Nazer, Mende; Lewis, Damien (2009). Slave: My True Story. PublicAffairs. ISBN 978-0-7867-3897-7. Sage, Jesse (2015). Enslaved: True Stories of Modern Day Slavery. St. Martin's Press. ISBN 978-1-250-08310-4. Sowell, Thomas (2010). "The Real History of Slavery". Black Rednecks and White Liberals. ReadHowYouWant.com. ISBN 978-1-4596-0221-2.
== Democracy == The Economist Intelligence Unit's Democracy Index 2019 ranked the status of democracy in Thailand 68th of 167 nations (1=best [Norway]); 167=worst [North Korea]). Other ASEAN nations were ranked: Malaysia, 43; Philippines, 54; Indonesia, 64; Singapore, 75; Myanmar, 122; Cambodia, 124; Vietnam, 136; and Laos, 155. Brunei was not ranked. The Economist Intelligence Unit's Democracy Index 2016 ranked Thailand 100 of 167 nations (1=best; 167=worst) for the state of its democracy by rating its electoral processes and pluralism, the state of its civil liberties, the functioning of its government, political participation and political culture. Other ASEAN nations ranked were Indonesia, 48; Philippines, 50; Malaysia, 65; Singapore, 70; Cambodia, 112; Myanmar, 113; Vietnam, 131; and Laos, 151.
The difficulty that has been encountered in finding contributory alleles for complex diseases and in replicating positive associations suggests that many complex diseases involve numerous variants rather than a moderate number of alleles, and the influence of any given variant may depend in critical ways on the genetic and environmental background. If many alleles are required to increase susceptibility to a disease, the odds are low that the necessary combination of alleles would become concentrated in a particular group purely through drift.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.